VAERS Explorer
Back to explore

Report #2884032

Received Feb 4, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
—
Recovered
Not recovered
Vaccinated
Jan 30, 2026
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS2UNK—

Symptoms (2)

HeadacheMyalgia

Symptom narrative

Headache; Muscle ache; This non-serious case was reported by a consumer via sales rep and described the occurrence of headache in a 65-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on an unknown date). On 30-JAN-2026, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced headache (Verbatim: Headache) and muscle pain (Verbatim: Muscle ache). The outcome of the headache and muscle pain were resolving. The reporter considered the headache and muscle pain to be related to Shingrix. The company considered the headache and muscle pain to be related to Shingrix. Additional Information: GSK Receipt Date: 01-FEB-2026 The batch number was not provided and we and unable to contact the reporter.